Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

La Jolla Proceeds With Additional Riquent Dosing Study

This article was originally published in The Pink Sheet Daily

Executive Summary

High doses of lupus agent appear to be "well-tolerated" in healthy volunteers, firm says. Dose-response data are being collected in response to FDA's "approvable" letter. La Jolla plans to add the information to ongoing pivotal trial.

You may also be interested in...



Prestara Changes Course: Development To Focus on Lupus Signs And Symptoms

Genelabs will no longer pursue a Prestara indication for prevention of loss of bone mineral density in women with lupus.

Genelabs To Meet With FDA Following Positive Open-Label Prestara Study

The study was an extension of a previous Phase III study that failed to meet its primary endpoint of increased bone mineral density at the lumbar spine.

Genelabs To Meet With FDA Following Positive Open-Label Prestara Study

The study was an extension of a previous Phase III study that failed to meet its primary endpoint of increased bone mineral density at the lumbar spine.

Related Content

Topics

UsernamePublicRestriction

Register

OM014142

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel